Almenoff June Sherie
Almenoff June Sherie's purchase track record
Almenoff June Sherie has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/17/2025 | TENX | $15K | +69.8% | +58.1% | +10.9% |
| 11/12/2024 | AVTX | $13K | -40.2% | -71.3% | -1.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Tenax Pauses TNX-103 Trial Enrollment, Seeks FDA Meeting. Tenax Therapeutics has temporarily paused enrollment in its LEVEL-2 trial for TNX-103 to amend study criteria. The company has also requested a meeting with the FDA to discuss these changes. This development is significant as it involves a key clinical trial, and the stock is currently trading near its 52-week low.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Avalo Therapeutics Reports Phase 2 Progress on IL-1β Program. Avalo Therapeutics disclosed Phase 2 validation for its IL-1β franchise, a development that could expand the company's pipeline in inflammatory disease treatments. The biotech firm also announced inducement stock grants to new hires under Nasdaq listing rules and scheduled participation in investor conferences, routine corporate activities that signal active business expansion. The stock trades within its 52-week range, with the analyst consensus target notably above current levels.
Transaction History
| ATNM | ▲ Buy | Grant | 18,000 | $0 | 9/2/2026 | View on chart |
| TENX | ▲ Buy | Open Market | 1,900 | $14K | 11/18/2025 | View on chart |
| TENX | ▲ Buy | Open Market | 93 | $665 | 11/17/2025 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 3,167 | — | 3/28/2025 | View on chart |
| AVTX | ▲ Buy | Open Market | 500 | $7K | 11/13/2024 | View on chart |
| AVTX | ▲ Buy | Open Market | 500 | $6K | 11/12/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Actinium Announces ATNM-400 Presentation and CFO Appointment
Actinium Pharmaceuticals will present early phase 1 data for its ATNM‑400 radiotherapy at the EANM 2026 meeting. The study is the first human trial of a non‑PSMA targeting therapy for metastatic prostate cancer. The company also added Dr. Matt David as chief financial officer, expanding its leadership team. These developments come as the stock trades near its 10‑touch support level of $1.14 and shows a volume spike.
Actinium Announces ATNM-400 Presentation and CFO Appointment. Actinium Pharmaceuticals will present early phase 1 data for its ATNM‑400 radiotherapy at the EANM 2026 meeting. The study is the first human trial of a non‑PSMA targeting therapy for metastatic prostate cancer. The company also added Dr. Matt David as chief financial officer, expanding its leadership team. These developments come as the stock trades near its 10‑touch support level of $1.14 and shows a volume spike.